CD40/ interleukin 4 (IL4) co-treatment of CLL patient cells has previously been shown to be a highly-effective and consistent method to simulate the CLL microenvironment [21,22]. The gene discussed is IL4; the disease is B-cell chronic lymphocytic leukemia.